Abstract
Alternative substrates for influenza vaccine production are needed to ensure adequate supplies. We evaluated the relative safety and immunogenicity of recombinant hemagglutinin (rHA) or trivalent inactivated vaccine (TIV) among 869 > or =65-year-old subjects in a randomized clinical trial. Virologic surveillance for influenza-like illness (ILI) was conducted during the 2006-2007 epidemic. Vaccines were well tolerated. Seroconversion rates vs. influenza A/H1N1 and H3N2 antigens were superior in the rHA group, but were inferior vs. influenza B; however, results for influenza B are confounded since the vaccine antigens were different. ILI frequencies were low and similar in both groups. Studies assessing relative immunogenicity of vaccines using identical B Ags are warranted.
Trial registration:
ClinicalTrials.gov NCT00395174.
Publication types
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Hemagglutinin Glycoproteins, Influenza Virus / immunology*
-
Humans
-
Influenza Vaccines / administration & dosage
-
Influenza Vaccines / adverse effects
-
Influenza Vaccines / immunology*
-
Multicenter Studies as Topic
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / immunology*
-
Vaccines, Inactivated / administration & dosage
-
Vaccines, Inactivated / adverse effects
-
Vaccines, Inactivated / immunology
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / adverse effects
-
Vaccines, Synthetic / immunology
Substances
-
Hemagglutinin Glycoproteins, Influenza Virus
-
Influenza Vaccines
-
Recombinant Proteins
-
Vaccines, Inactivated
-
Vaccines, Synthetic
Associated data
-
ClinicalTrials.gov/NCT00395174